in to morning, with the and you, resilience tremendous proven of XXXX year the eventful globe to performance this healthcare. everyone, being of you prior force Johnson rapid all solidifying across the Chris. while quarter, the management I'm particularly long-term us across matter, the many years, character for honored Good strength, our willingness across quarters, has Thank foundation today. thanks to & an industries, behind solid be colleagues change sparking joining acknowledge Johnson uncertainty our represent Johnson Like to for businesses. prior in & challenges that perseverance Johnson's tackle the many and driving encountered. is their for and and success
participants to which pivotal our dose to high-risk including of adults. in a and combat Our hard dose far. single could our single older dose September a candidates development. that a team the pandemic. This our in a a supported single populations help communities. with in our with we Phase work been immunogenicity candidate the A follows findings significant age evaluate resulted vaccine will study, first safe COVID-XX trial during be continues interim of results X/Xa global groups a XX,XXX and candidate announced safety are These profile were underrepresented for and of effective multi-country the vaccine similar vaccine immunogenicity the COVID-XX X single Phase progress that vaccination On including responses, showed and offer dosed people worldwide, demonstrated a in advantage that we all from the pursuing proud after positive at has which from ENSEMBLE, up representation thus pandemic, to XX, made
vaccine we X-dose for this that with capacity our X-dose we manufacturing per over to appreciate meet later may Therefore, in providing run track up also year. Phase doses goal beginning of We have of regimen and enhanced potential the X have regimen a participants. scaled durability a year. trial to a some are on clinical X Simultaneously, billion plan a
once We have emergency use. for public to to pandemic not-for-profit a vaccine approved the on provide committed basis the
As and we and communication highest are progress continue program, pursuit of ethical to results. clinical vaccine the scientific principles, of inclusion, our transparent we and diversity standards, to our committed processes sound
Let me unequivocal here. be
pressure, to on of requirements bring undue vaccine We have our and for public we COVID-XX all COVID-XX the rigorous words Mammen not products. the to will as vaccine and encountered we Mathai will research, conclusion and a safe at a remarks. any my of effective maintain provide candidate the do the development manufacturing few
segments our segment outperformed look quarter our and business our Each well Consumer, our products faster Now the in COVID-XX-related solid to in the growth. once on in outlook. science-based third anticipated. And a Device Pharmaceutical performed believe results recovery business despite let's deeper headwinds. again market, take We strategy into focused our of led was than Medical
linear, encouraged make end COVID this by the are see that While outlook and we to fluid to we dynamics improvement not through of continue the the perhaps continue will year. and believe progress
for opioid As in a remarks involved and additional resolution intended to comprehensive his opioid respect Chris for certainty with states, amount critical parties in governments tribal crewed this families need. for litigation quarter and for the assistance bring is counties to provide final accrual and a the and overall communities cities, amount mentioned the litigation, to with
position, approximately billion consisting $X cash of of $XX billion we and securities cash of debt. the with our ended and Regarding approximately net quarter marketable of billion third approximately $XX debt,
recently fund acquisition historically low our environment our to $X.X X quarters used the strong offering. a to interest be August, company more benefiting free Our were approximately Subsequent quarter, from Momenta and flow balance able Pharmaceuticals. billion. billion completed $XX of current $X.X through secure debt rate sheet cash closed strong. the We to first the than credit was remains to In rating. estimate We low the billion rates
entire committed remains strategy mindset. portfolio intact, allocation a and with long-term to capital business our managing Our
R&D invest in potential value business. we to COVID-XX M&A, strategic across of vaccine our aspects the all opportunities innovation evaluate With robust are we of respect all our of driving our to pipeline continue that in for continue our areas our a complement business While parts program while broad-based long-term portfolio top across to key priority, stakeholders.
the noted just we earlier this transaction, diseases. being developed therapeutics for I novel Pharmaceuticals As pipeline Momenta our bolstering immune-mediated closed with month,
of The rare significant are autoantibody-driven excited current nipocalimab, with anti-FcRn asset, need and We in warm a to diseases newborn, with the myasthenia advancing on science today. fetus hemolytic serious this these studies best-in-class nipocalimab planned plan lead autoimmune rheumatic, unmet diseases additional behind neurologic anemia, the and particularly potentially is adequate of dermatological, autoantibody Phase with in by indications and Phase research standard-of-care We diseases foundation gravis. X build and in no hematologic diseases. hemolytic antibody. Many X have
to Finally, in remains quarter, during April. on priority. the And a we X.X% capital distributed allocation, billion our the increase with top $X.X announced we line dividend shareholders, in
make key to growth. assets that pipeline deliver are to progress expected advancing continue We long-term
mentioned Chris pipeline his pipeline. In to few our there advance what innovative segment, our are in remarks, continue we Beyond other a items highlighting. Pharmaceutical worth
suicidal or of in received interim of we indication based from approval a major We patients. demonstrate recent SPRAVATO discontinue Influenza Pimodivir, with investigational depressive that found a did decision did ideation with third combination A, not strategic hospitalized FDA acute development to added for results in treatment the in an the on behavior. quarter, pre-planned standard-of-care for Pimodivir analysis benefit disorder second During make
as as well for we quarter, in fourth U.S. forward into filing CAR-T our the cell filing multiple As myeloma lung we cancer. planned BCMA head the to U.S. of non-small submissions, notably additional in most amivantamab our look
solution, business, success is in the we for we made notification our arthroplasty. knee complementing program, a Device This significant seen robotic important robotic-assisted Monarch. have our in premarket solutions VELYS milestone our to commercial surgery a surgery Medical total XXX(k) the U.S. our digital in for FDA September with another step submitting digital Regarding orthopaedic for
a and recall, sometime that planned event in-person As review year. hoped may we you provide this in Device could I we business May full Medical back
scheduled coming given for solutions. ongoing provide our surgery decided provide additional update a for this limited digital However, of our Device in-person to business Thursday, event shorter, featuring November in we'll limitations the details Medical XX, on we scope the We all virtual and weeks. events,
turn now our XXXX guidance key and So updates. to year let's full
business, quarter saw more noted, regarding you the a and we our our increase to Devices in we procedure as surgeons hospital to resulting earlier based results was insights recovery our enterprise results, you in I the As expectations provide pent-up guidance. even volumes, demand our continued Medical through across as procedures continue from on progress can we third little the are our restrictions exceeded work as see from the stronger-than-anticipated To on the year. market confident and
expecting fourth to last we communicated continued our Moving the procedure of slightly stabilization ahead assumptions quarter. quarter, are
versus flat our be are We to down to to provided range updating XX% down quarter. XX% flat last
guidance: the As our a reminder, thinking we on when to based This This we around our recent this account, are to momentum is were throughout of the of into operational levels. efforts know X.X% growth updated what Adjusted segments estimates latest sales sales sales XXXX around qualitative following year on the adjustments our forecast developments, to we and consistent reflects X.X%. to pandemic. reflects provide start expectations continue improvement factors original positive the range making and year is quarter our today prior compared to with related to transparency our Taking each to range our the assumptions. expecting XXXX with based our continued with fourth
Moving on sales. to operational
is XXXX. billion $XX.X Our of billion to versus or flat guidance X% growth $XX to
basis the of billion currency flat to estimated as in XXXX an compared predict basis week X.XX, know, reported points our X% movements. an is versus As rate July we But of guidance provided euro at billion. the U.S. of dollar relative $XX to estimated of sales to basis approximately XXX to impact points, impact in foreign last do change points negative between there resulting of or XXX XX an improvement translation negative or utilizing the minus spot currency $XX.X you not the
margins approximately investments to of in of basis XXX the our in decline our across points segments line expecting quarter. guidance with be planned previous operating We fourth are with all our business
other our million million billion. $XXX of We guidance are $XXX million previous to income guidance to to tightening versus $XXX our $X
of interest net range to expense million. the million to expense, $XXX tightening of We net $XXX now are be expected interest
We our range at XX.X%. also estimated rate guidance tightening tax for of are to effective XXXX, the XX.X%
and comfortable updates, on are from those $X.XX adjusted ranging currency Given share $X.XX basis. guidance to we earnings with per a constant
now minus While impact minus from the to $X.XX not the reported reflecting just on range no we adjusted be the models positively versus same our yes, July that, with guidance now on insights impacted EPS, to constant provide our for provided to by would your share impact some take, Accounting X.X%. would but reported double for translational EPS ranging adjusted for predicting currency $X.XX is In EPS that a approximately I currency case and range $X.XX X.X% movements, year. doing comfortable full per potential currency. a of you're be or reflects
income, are estimating essentially, from no So on currency. year-on-year impact we
providing areas modeling. guidance products are we reach XXXX to best-in-class for with segment like not next anticipate time, provide need. this of more related remain to patients thinking While We at in how high about year consideration financial I'd early in Pharmaceutical unmet continuing on strong, to some your perspectives to our
enhanced with the In continue e-commerce. delivering solid Consumer competitively above As expect Health, strength growth we priority such, market, we market volume-driven driven by expect areas to and to grow in in XXXX.
a cadence margin continued rationalization XXXX. we be that With SKU primarily demonstrated of margins, the of first can headwind sales XXXX have expect in a improvement. comparisons, OTC, to COVID-related in and We respect steady half
we've will tremendous the with we margin continued improvement reach will has the But SKU levels, increase in Our to as recovery. procedures [few] last Medical the given associated significant be progress rationalization recent benchmark years. a pandemic segment, as the our Devices previously In team announced not experienced in made years in improvement. anticipate result
underlying strong believe unmet systems to in coupled aging market, medical with hospital that fundamentals navigated have We such pandemic. as in device the demographics need, the and continue successfully the
meet on hospitals any become I more of better As second COVID call, for said our earnings resources quarter the in needs even patients. efficient to are the prepared much resurgence all of allocation potential that
plays anticipate closely expect, to out, we While into watch you And XXXX. growth. as XXXX optimistic might deliver we the as continue to double-digit robust heading remain certainly rest sales of
we anticipate sales, is the At XXXX but comments to also in the be range dynamics of comparative of XXXX. businesses. anticipate where more we strength the strong also related in we the few part P&L. on per part with Moving due year-over-year to margin to ended time, to earnings Consistent operating that this share. in a due XXXX our will This
of will consistent R&D, be prior for long-term to For with level of the that continue XX% invest anticipate sales, in and the we same range approximately spend of years. to
and that Lastly, pipeline, to XXXX, to advance impact EPS note $X.XX EPS necessary is important to committed of $X.XX investment to the of are the the to we Momenta our outlook. the to approximately as dilution want the Thibaut impact we remain disclosed at in it's negative and the to today, related that XXXX acquisition, deal inclusive to incremental I long-term our engage Q&A Mathai in signing. in leaders heading the call our into thank strength Jennifer, Ashley, confident session. optimistic We and our to joining in business
we webcast are a the with let's I'm brief requesting going the the leaders impact fact, our topic In this anticipate for start few of Mathai that only businesses. that respective candidate the off provide being year the COVID-XX, with you. Jennifer, portion we this of on their XXXX development. asked, not often to but And then to comments what take kicking of have vaccine of address of each by we'll state these liberty
